News Roundup: October 10 to October 14

The approval for tovorafenib (Ojemda) was based on data from the phase 2 FIREFLY-1 trial, in which the therapy demonstrated an overall repose rate of 67%.

Wendy Crouse, DVM, an independent house call veterinarian with Heal House Call Veterinarian, sat down with Drug Topics to discuss how the adoption of e-prescribing has transformed her practice.

Abeona Therapeutics’ pz-cel is an investigational autologous, COL7A1 gene-corrected epidermal sheet therapy for the treatment of recessive dystrophic epidermolysis bullosa.

Kevin Hope, RPh, senior director of pharmacy education at Pharmcon, joined Drug Topics to discuss pharmacy compounding from the new USP changes and the importance of education around compounding best practices.

A higher patient-rated therapeutic alliance was associated with improvements in depression outcomes up to 1 year after treatment.

In case you missed it, this week we had news about potential pharmacy unions, states' regulation of PBMs, rising insulin costs, and more.